skip to main content

News Archive

Date: 08/22/2022
Within a pancreatic cancer tumor, different cell types interact to facilitate the tumor’s growth. Researchers see disrupting this metabolic crosstalk as a compelling target for treatment.
Date: 08/16/2022
The Rogel Cancer Center has submitted the 2022 grant renewal application for the National Cancer Institute’s Cancer Center Support Grant. Every five years, the cancer center must submit a renewal application for continued funding under the CCSG. Earlier this summer, the Rogel Cancer Center team completed and submitted the most recent CCSG renewal application.
Date: 08/08/2022
Coaching patients to voice their concerns about their medical care and advocate for themselves can offset physicians’ racial bias so it doesn’t lead to inferior experiences for Black patients, a University of Michigan-led study found.
Date: 07/27/2022
Patients with relapsed multiple myeloma are resistant to commonly used treatments. Researchers are one step closer to understanding the genetic reason why.
Date: 07/26/2022
The University of Michigan Rogel Cancer Center was rated the best cancer hospital in Michigan and among the best nationwide by U.S. News & World Report “Best Hospitals” rankings for 2022-2023. Rogel is the only Michigan cancer program to be ranked.
Date: 06/20/2022
Scientists have been working to make a mouse model of this tumor to better understand the disease biology to support preclinical testing of novel drugs, but no one before has been successful. A Merkel cell polyomavirus is believed to cause about 80% of these tumors, but researchers have been unable to definitively show this in vivo.
Date: 06/07/2022
A study published in Nature Communications, led by Imad Shureiqi, M.D., shows that, pre-cancerous pancreatic lesions in mice, similar to those found in humans, contain higher levels of the transcriptional receptor peroxisome proliferator activated receptor-delta (PPARδ).
Date: 06/03/2022
Scientists at the University of Michigan Rogel Cancer Center were optimistic when they identified a small molecule that blocked a key pathway in brain tumors. But there was a problem: How to get the inhibitor through the bloodstream and into the brain to reach the tumor. In collaboration with multiple labs, the teams fabricated a nanoparticle to contain the inhibitor, and the results were even better than expected.
Date: 05/26/2022
More than 30 Rogel Cancer Center-led research efforts will be presented during the 2022 ASCO Annual Meeting, running June 3-7 at McCormick Place in Chicago, Illinois, and online.
Date: 05/26/2022
Men with advanced prostate cancer taking abiraterone or enzalutamide plus hormone therapy were at higher risk of serious medical issues than their peers undergoing hormone therapy alone.